Drugs / Lacticaseibacillus casei AMBR2
Lacticaseibacillus casei AMBR2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06057558 | Jan 2022 → Nov 2024 | cystic fibrosis | University Hospital, Antwerp | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lacticaseibacillus casei AMBR2 | “Throat spray containing Lacticaseibacillus casei AMBR2” NCT06057558 ↗ |
| Modality | Other / unclassified | “Daily use of a probiotic throat spray for 4 weeks” NCT06057558 ↗ |
| Route | Other | “Daily use of a probiotic throat spray for 4 weeks” NCT06057558 ↗ |